- Intranasal hydrocodone extended release (ER) has a low abuse potential compared with hydrocodone powder and hydrocodone bitartrate ER capsules (Zohydro ER).
Why this matters
- A single-dose, randomized, double-blind, quadruple-dummy, active- and placebo-controlled crossover study identified 170 healthy adults to assess the abuse potential of hydrocodone formulations.
- Funding: Teva Branded Pharmaceutical Products R&D, Inc.
- Mean efficacy of drug liking “at the moment” was significantly lower for intranasal hydrocodone ER (Maximum effect [Emax], 72.8) vs hydrocodone powder (Emax, 80.2; P=.004) and bitartrate ER capsules (Emax, 83.2; P<.001>
- Overall drug liking, 24 h after administration was significantly lower with intranasal hydrocodone ER (Emax, 68.5) compared with hydrocodone powder (Emax, 77.1; P=.004) and bitartrate ER capsules (Emax, 79.8; P<.001>
- Overall adverse events with placebo, intranasal hydrocodone powder, intranasal hydrocodone ER tablets and bitartrate ER capsules were 18%, 53%, 52%, and 61%, respectively.
- Most adverse events were mild and resolved.
- Single-center study.
Coauthored with Anand Ramanathan, PharmD